Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

As discussed below, in connection with its participation in the
35th Annual J.P. Morgan Healthcare Conference in San Francisco,
California beginning on January9th, 2017, Agile Therapeutics,Inc.
(the Company) updated its corporate presentation to, among other
things discussed below, include disclosure that the Company had
$48.8 million of cash and cash equivalents as of December31,
2016.

Because the Companys financial statements for the year ended
December31, 2016 have not yet been finalized or audited, the
preliminary statement of the Companys cash and cash equivalents
as of December31, 2016 in this Item 2.02 is subject to change,
and the Companys actual cash and cash equivalents as of the end
of this period may differ materially from this preliminary
estimate. Accordingly, you should not place undue reliance on
this preliminary estimate.

Item 7.01 Regulation FD Disclosure

Beginning on January9, 2017, the Company will participate in the
35th Annual J.P. Morgan Healthcare Conference in San Francisco,
California. The Company has updated its corporate presentation
that it intends to use in connection with presentations at
conferences and meetings with investors. The updates primarily
include disclosure regarding the Companys cash and cash
equivalents as of December31, 2016 as stated above and a summary
of the top-line results of the Companys SECURE Phase 3 clinical
trial (SECURE) that were previously announced on January3, 2017,
including additional context regarding discontinuation rates and
serious adverse events (SAEs) observed in previous Phase 3
clinical trials for other approved hormonal contraceptive
products.

The information included in this Current Report on Form8-K
(including Exhibit99.1) shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference into any filing made by the Company under the
Exchange Act or the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such a
filing.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

About Agile Therapeutics, Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information

Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session up +0.11 at 2.80 with 1,515,674 shares trading hands.